FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089240968> ?p ?o ?g. }

• W3089240968 endingPage "333" @default.
• W3089240968 startingPage "325" @default.
• W3089240968 abstract "Objective To evaluate the cost-effectiveness of tofacitinib versus other treatment options currently available for the management of adult patients with moderate-to-severe ulcerative colitis, who have had an inadequate response, loss of response, or were intolerant to conventional therapy or a biologic agent, in Greece. Methods A Markov model was adapted for projecting lifetime costs and outcomes, for a cohort of patients with moderate-to-severe ulcerative colitis from a Greek payer perspective. Patients entered the model in the active ulcerative colitis state and transitioned to a remission or response state or they underwent colectomy. Following an initial 8-week induction treatment period, patients received maintenance therapy until loss of response. Nonresponders could switch to up to two subsequent biologic lines. Clinical efficacy, adverse event rates and utilities derived from OCTAVE trials and a network-meta-analysis (NMA), while adverse event-related disutilities were obtained from the literature. Information on treatment pathways and resource use was provided by an advisory board due to a lack of local data. Unit costs derived from official national sources (€, 2018). Results Over a life-time horizon, treating moderate-to-severe active ulcerative colitis with tofacitinib resulted in additional quality-adjusted life-years (QALYs) and lower total costs compared to vedolizumab (0.018; €6408), infliximab (biosimilar) (0.009; €3031), golimumab (0.042; €1988) and infliximab (originator) (0.009; €6724). Hence, tofacitinib was estimated to be dominant over all comparators. Conclusion The results of the analysis suggest that in the Greek setting, tofacitinib could be considered a cost-effective (dominant) treatment option for the treatment of patients with moderate-to-severe active ulcerative colitis." @default.
• W3089240968 created "2020-10-01" @default.
• W3089240968 creator A5011048096 @default.
• W3089240968 creator A5014525409 @default.
• W3089240968 creator A5038517675 @default.
• W3089240968 creator A5043495575 @default.
• W3089240968 creator A5073478319 @default.
• W3089240968 creator A5079694096 @default.
• W3089240968 creator A5086509103 @default.
• W3089240968 date "2020-09-23" @default.
• W3089240968 modified "2023-10-14" @default.
• W3089240968 title "Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece" @default.
• W3089240968 cites W1537955720 @default.
• W3089240968 cites W1971432042 @default.
• W3089240968 cites W1984705525 @default.
• W3089240968 cites W2002040688 @default.
• W3089240968 cites W2027450031 @default.
• W3089240968 cites W2062766962 @default.
• W3089240968 cites W2064485014 @default.
• W3089240968 cites W2068407303 @default.
• W3089240968 cites W2070852224 @default.
• W3089240968 cites W2083759302 @default.
• W3089240968 cites W2090224700 @default.
• W3089240968 cites W2092863985 @default.
• W3089240968 cites W2112768046 @default.
• W3089240968 cites W2126103084 @default.
• W3089240968 cites W2146692972 @default.
• W3089240968 cites W2155367723 @default.
• W3089240968 cites W2156250460 @default.
• W3089240968 cites W2162805528 @default.
• W3089240968 cites W2165582664 @default.
• W3089240968 cites W2171297959 @default.
• W3089240968 cites W2329063300 @default.
• W3089240968 cites W2611548364 @default.
• W3089240968 cites W2766046358 @default.
• W3089240968 cites W2774339715 @default.
• W3089240968 cites W2788613077 @default.
• W3089240968 cites W2799839068 @default.
• W3089240968 cites W2911373719 @default.
• W3089240968 cites W2940490436 @default.
• W3089240968 cites W2966849593 @default.
• W3089240968 cites W2995883418 @default.
• W3089240968 cites W3150733764 @default.
• W3089240968 cites W4210972027 @default.
• W3089240968 cites W4230633180 @default.
• W3089240968 doi "https://doi.org/10.1097/meg.0000000000001916" @default.
• W3089240968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32976189" @default.
• W3089240968 hasPublicationYear "2020" @default.
• W3089240968 type Work @default.
• W3089240968 sameAs 3089240968 @default.
• W3089240968 citedByCount "6" @default.
• W3089240968 countsByYear W30892409682021 @default.
• W3089240968 countsByYear W30892409682022 @default.
• W3089240968 countsByYear W30892409682023 @default.
• W3089240968 crossrefType "journal-article" @default.
• W3089240968 hasAuthorship W3089240968A5011048096 @default.
• W3089240968 hasAuthorship W3089240968A5014525409 @default.
• W3089240968 hasAuthorship W3089240968A5038517675 @default.
• W3089240968 hasAuthorship W3089240968A5043495575 @default.
• W3089240968 hasAuthorship W3089240968A5073478319 @default.
• W3089240968 hasAuthorship W3089240968A5079694096 @default.
• W3089240968 hasAuthorship W3089240968A5086509103 @default.
• W3089240968 hasConcept C126322002 @default.
• W3089240968 hasConcept C141071460 @default.
• W3089240968 hasConcept C197934379 @default.
• W3089240968 hasConcept C2776207728 @default.
• W3089240968 hasConcept C2777138892 @default.
• W3089240968 hasConcept C2777575956 @default.
• W3089240968 hasConcept C2778886723 @default.
• W3089240968 hasConcept C2779134260 @default.
• W3089240968 hasConcept C2780132546 @default.
• W3089240968 hasConcept C2780479503 @default.
• W3089240968 hasConcept C2781290027 @default.
• W3089240968 hasConcept C71924100 @default.
• W3089240968 hasConceptScore W3089240968C126322002 @default.
• W3089240968 hasConceptScore W3089240968C141071460 @default.
• W3089240968 hasConceptScore W3089240968C197934379 @default.
• W3089240968 hasConceptScore W3089240968C2776207728 @default.
• W3089240968 hasConceptScore W3089240968C2777138892 @default.
• W3089240968 hasConceptScore W3089240968C2777575956 @default.
• W3089240968 hasConceptScore W3089240968C2778886723 @default.
• W3089240968 hasConceptScore W3089240968C2779134260 @default.
• W3089240968 hasConceptScore W3089240968C2780132546 @default.
• W3089240968 hasConceptScore W3089240968C2780479503 @default.
• W3089240968 hasConceptScore W3089240968C2781290027 @default.
• W3089240968 hasConceptScore W3089240968C71924100 @default.
• W3089240968 hasIssue "3" @default.
• W3089240968 hasLocation W30892409681 @default.
• W3089240968 hasLocation W30892409682 @default.
• W3089240968 hasOpenAccess W3089240968 @default.
• W3089240968 hasPrimaryLocation W30892409681 @default.
• W3089240968 hasRelatedWork W2006826205 @default.
• W3089240968 hasRelatedWork W2042655884 @default.
• W3089240968 hasRelatedWork W2105263940 @default.
• W3089240968 hasRelatedWork W2152399325 @default.
• W3089240968 hasRelatedWork W2177005649 @default.
• W3089240968 hasRelatedWork W2995236676 @default.
• W3089240968 hasRelatedWork W3146667541 @default.

• next